Pharmacyclics Incorporated (PCYC)

PCYC (NASDAQ:Drugs)
$85.61
pos +0.01
+0.01%
Today's Range: 82.55 - 85.90 | PCYC Avg Daily Volume: 787,500
Last Update: 05/24/13 - 4:00 PM EDT
Volume: 478,148
YTD Performance: 48.15%
Open: $85.25
Previous Close: $85.60
52 Week Range: $30.06 - $95.85
Oustanding Shares: 72,783,040
Market Cap: 6,230,228,224
6-Month Chart
TheStreet Ratings Grade for PCYC
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 4 4 4 4
Moderate Buy 1 0 0 0
Hold 6 7 7 6
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.18 2.27 2.27 2.20
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 73.15
Price Earnings Comparisons:
PCYC Sector Avg. S&P 500
73.15 73.80 17.70
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-5.28% 160.53% 1,265.23%
GROWTH 12 Mo 3 Yr CAGR
Revenue 895.90 0.00 0.00
Net Income 0.00 -1.51 0.00
EPS 0.00 -1.19 0.00
Earnings for PCYC:
EBITDA 0.01B
Revenue 0.08B
Average Earnings Estimates
Qtr (06/13) Qtr (09/13) FY (12/13) FY (12/14)
Average Estimate $-0.07 $-0.16 $-0.35 $-0.57
Number of Analysts 5 8 9 10
High Estimate $0.00 $0.35 $1.94 $1.39
Low Estimate $-0.23 $-0.46 $-1.61 $-3.14
Prior Year $-0.24 $1.02 $0.17 $-0.35
Growth Rate (Year over Year) 72.50% -115.69% -306.54% -62.91%
Update Chart
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
MikeOinSATX
MikeOinSATX: RT @BioDueDiligence: Repost with proper thanks to @zDonShimoda - PI3K inhibitors at Lugano conference: http://t.co/b0OMvGC3kc $INFI $GILD $PCYC
41 seconds ago from Twitter for Android
BioDueDiligence
BioDueDiligence: Repost with proper thanks to @zDonShimoda - PI3K inhibitors at Lugano conference: http://t.co/b0OMvGC3kc $INFI $GILD $PCYC
53 minutes ago from web
msljobs
msljobs: $pcyc looking for MSLs nationwide http://t.co/mwOV48kZHx
1 day ago from HootSuite
msliq
msliq: $pcyc looking for MSLs nationwide http://t.co/L6OFzlozie
1 day ago from HootSuite
msljobs
msljobs: Thanks $PCYC $ONXX and BestMSL for using http://t.co/kAdlW4b5dx to source your medical affairs team!
1 day ago from HootSuite
msliq
msliq: Thanks $PCYC $ONXX and BestMSL for using http://t.co/OKgXxtaf5y to source your medical affairs team!
1 day ago from HootSuite
janechin
janechin: Thanks $PCYC $ONXX and BestMSL for using http://t.co/x7bqaeIyQ1 to source your medical affairs team!
1 day ago from HootSuite
DDNotesMaker
DDNotesMaker: A due diligence report for $PCYC is ready at http://t.co/Te0hfJq2nt
1 day ago from DDNotesMakerPost
DDNotesMaker
DDNotesMaker: A due diligence report for $PCYC is ready at http://t.co/Te0hfJq2nt
1 day ago from DDNotesMakerPost
DDNotesMaker
DDNotesMaker: A due diligence report for $PCYC is ready at http://t.co/Te0hfJq2nt
1 day ago from DDNotesMakerPost

bullishPharmacyclics estimates, target raised at Credit Suisse

Feb 15, 2013 | 7:43 AM EST

Shares of PCYC now seen reaching $90, accoridng to Credit Suisse. Estimates also increased, as Ibrutinib should drive growth. Outperform rating. 

bullishPharmacyclics initiated at Credit Suisse

Jan 15, 2013 | 8:07 AM EST

Shares of PCYC rated new Outperform, Credit Suisse said. $79 price target. Most derisked pure play in oral lymphoma/leukemia drug class.

bearishPharmacyclics downgraded at Lazard

Jan 14, 2013 | 8:49 AM EST

PCYC was downgraded to Neutral, Lazard Capital Markets said. Company lacks near-term catalysts.

Off the Charts

By

Scott Redler

 | Jan 8, 2013 | 6:25 PM EST

It's encouraging now to see the S&P hold onto most of those post fiscal cliff gains.

The Next Big Thing In Biotech: ASH Meeting

By

Adam Feuerstein

 | Dec 7, 2012 | 6:00 AM EST

Adam Feuerstein, Sr. Columnist for TheStreet, says the American Society of Hematology meeting is the next big thing to watch in biotech.

Two More to Short

By

Timothy Collins

 | Nov 30, 2012 | 3:13 PM EST

My list doubles in size.

bearishPharmacyclics downgraded at Needham

Aug 2, 2012 | 7:45 AM EDT

PCYC was downgraded from Buy to Hold, Needham said. Valuation call. 

 

updatePharmacyclics rated new Market Perform at Bernstein

Jul 13, 2012 | 7:56 AM EDT

PCYC was initiated with a Market Perform rating, Bernstein said. $51 price target. Valuation call, as the stock is up 300% year-to-date. Also have below-consensus view of the company's key product. 

Promising but Unpredictable Biotechs

By

Kate Stalter

 | Jul 3, 2012 | 12:04 PM EDT

These mid-caps are volatile, but a merger or major announcement could send them soaring.

Delayed Reaction

By

James "Rev Shark" DePorre

 | Jul 2, 2012 | 1:16 PM EDT

The weak ISM number will eventually matter, but for now, traders are focused on technical conditions.

Columnist Conversation / Market Updates

Easy Money (Part One)
By

Doug Kass

 | May 25, 2013 | 8:45 AM EDT
"It's the lure of easy money. It has a very strong appeal." -Glenn Frey, Smuggler's Blues Investors bor...

SPX cash daily chart
By

Carolyn Boroden

 | May 24, 2013 | 3:24 PM EDT
There is no technical damage on the daily chart of $SPX at this point. Actually this decline is only similar to prior d...
See more »

Our Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.